Media hub

The Centenary Institute is delighted to announce that Professor Marc Pellegrini will join the Centenary Institute as its new Executive Director. A physician, immunologist and internationally renowned research scientist, Professor Pellegrini has over 20 years of experience working on chronic infections.

Research led by the Centenary Institute, the University of Technology Sydney and Ghent University Hospital, Belgium has identified a new therapeutic approach for chronic obstructive pulmonary disease (COPD) – the targeting and inhibition of a protein called RIPK1.

Research led by the Centenary Institute and the University of Sydney – focused on the development of a new nasal COVID-19 vaccine – has received close to $1m in grant funding from the NSW COVID-19 Vaccine Acceleration Research Grants Program.

World-leading research into heart muscle disease has been boosted with the Centenary Institute’s Associate Professor Mathias Francois and team awarded a National Health and Medical Research Council (NHMRC) Ideas Grant to investigate left ventricular non compaction cardiomyopathy (LVNC).

Researchers from the Centenary Institute have found that concealed cardiomyopathy is an important cause of sudden cardiac death where no cause is found from autopsy – and that genetic testing can help identify cases of concealed cardiomyopathy which provides a cause of death and also helps guide care of surviving relatives.

Researchers from the Centenary Institute and the University of Sydney have developed a new nasal vaccination strategy that induces potent lung immunity and protection against the SARS-CoV-2 coronavirus.

Genetic testing can diagnose cardiomyopathy – a disease of the heart muscle – in children and help detect who will have heart failure and require a transplant, a new study has found.

Centenary Institute researchers in the Agnes Ginges Centre for Molecular Cardiology have secured $2.7 million in funding for nationally significant research into cardiovascular disease and sudden cardiac death.

The Centenary Institute and the University of Sydney, together with collaborators, have been awarded an AU$19 million contract from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), to develop the next generation of tuberculosis (TB) vaccines.

Researchers at the Centenary Institute and the University of Technology Sydney have identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease (COPD), an inflammatory lung disease that causes airway blockage and that makes it difficult to breathe.

The Centenary Institute welcomes the NSW Government’s commitment to fund a new biomedical complex in Camperdown. The Chair of the Centenary Institute Board, Joseph Carrozzi AM, and its Executive Director, Professor Mathew Vadas AO, are thrilled that a biomedical complex, the Sydney Biomedical Accelerator (SBA), will now be a reality.

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19.